Phase III trial of empagliflozin in adults with heart failure and reduced ejection fraction meets primary endpoint

In the EMPEROR-Reduced Phase III trial, empagliflozin was superior to placebo in decreasing the risk of a composite primary endpoint of cardiovascular death or hospitalisation from heart failure when added to standard of care (results to be presented at ESC Congress in August).


Biospace Inc.